Clinical trialNANo longer available
68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors
68Ga DOTA-TATE PET/CT in the Evaluation of Patients With Somatostatin Receptor Positive Tumors
- Outcome
- Outcome unknown
- Phase
- NA
- Status
- No longer available
- Study type
- Expanded access
- Sites
- 1
- Sponsor
- Other
- Results posted
- No
- Last update
- 23 August 2017
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The primary objective of the study is to evaluate 68Ga-DOTA TATE PET/CT for staging and monitoring response to chemotherapy in patients with carcinoid, neuroendocrine tumors, medullary thyroid cancer and other cancers expressing somatostatin receptors.